PMID- 33424871
OWN - NLM
STAT- MEDLINE
DCOM- 20210707
LR  - 20210707
IS  - 1664-3224 (Electronic)
IS  - 1664-3224 (Linking)
VI  - 11
DP  - 2020
TI  - Toxicities of Chimeric Antigen Receptor T Cell Therapy in Multiple Myeloma: An 
      Overview of Experience From Clinical Trials, Pathophysiology, and Management 
      Strategies.
PG  - 620312
LID - 10.3389/fimmu.2020.620312 [doi]
LID - 620312
AB  - In the last few years, monoclonal antibodies (mAbs) such as elotuzumab and 
      daratutumab have brought the treatment of multiple myeloma (MM) into the new era 
      of immunotherapy. More recently, chimeric antigen receptor (CAR) modified T cell, 
      a novel cellular immunotherapy, has been developed for treatment of 
      relapsed/refractory (RR) MM, and early phase clinical trials have shown promising 
      efficacy of CAR T cell therapy. Many patients with end stage RRMM regard CAR T 
      cell therapy as their "last chance" and a "hope of cure". However, severe adverse 
      events (AEs) and even toxic death related to CAR T cell therapy have been 
      observed. The management of AEs related to CAR T cell therapy represents a new 
      challenge, as the pathophysiology is not fully understood and there is still no 
      well-established standard of management. With regard to CAR T cell associated 
      toxicities in MM, in this review, we will provide an overview of experience from 
      clinical trials, pathophysiology, and management strategies.
CI  - Copyright (c) 2020 Zhou, Rasche, Kortum, Danhof, Hudecek and Einsele.
FAU - Zhou, Xiang
AU  - Zhou X
AD  - Department of Internal Medicine II, University Hospital of Wurzburg, Wurzburg, 
      Germany.
FAU - Rasche, Leo
AU  - Rasche L
AD  - Department of Internal Medicine II, University Hospital of Wurzburg, Wurzburg, 
      Germany.
FAU - Kortum, K Martin
AU  - Kortum KM
AD  - Department of Internal Medicine II, University Hospital of Wurzburg, Wurzburg, 
      Germany.
FAU - Danhof, Sophia
AU  - Danhof S
AD  - Department of Internal Medicine II, University Hospital of Wurzburg, Wurzburg, 
      Germany.
FAU - Hudecek, Michael
AU  - Hudecek M
AD  - Department of Internal Medicine II, University Hospital of Wurzburg, Wurzburg, 
      Germany.
FAU - Einsele, Hermann
AU  - Einsele H
AD  - Department of Internal Medicine II, University Hospital of Wurzburg, Wurzburg, 
      Germany.
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
PT  - Review
DEP - 20201223
PL  - Switzerland
TA  - Front Immunol
JT  - Frontiers in immunology
JID - 101560960
RN  - 0 (Antigens, Neoplasm)
RN  - 126465-35-8 (Perforin)
RN  - EC 3.4.21.- (Granzymes)
SB  - IM
MH  - Antigens, Neoplasm/immunology
MH  - Brain Diseases/etiology/physiopathology
MH  - Cell Degranulation
MH  - Clinical Trials as Topic
MH  - Cytokine Release Syndrome/etiology/physiopathology/therapy
MH  - Disease Management
MH  - Endothelium, Vascular/metabolism
MH  - Granzymes/metabolism
MH  - Hospitalization
MH  - Humans
MH  - Immunotherapy, Adoptive/*adverse effects
MH  - Lymphocyte Activation
MH  - Multiple Myeloma/*therapy
MH  - Palliative Care
MH  - Pancytopenia/etiology
MH  - Perforin/metabolism
MH  - T-Cell Antigen Receptor Specificity
MH  - T-Lymphocyte Subsets/immunology
PMC - PMC7793717
OTO - NOTNLM
OT  - CAR T cell
OT  - clinical trial
OT  - management
OT  - multiple myeloma
OT  - pathophysiology
OT  - toxicity
COIS- MH is listed as an inventor on patent applications and granted patents related to 
      CAR-T technologies that have been filed by the Fred Hutchinson Cancer Research 
      Center, Seattle, WA and by the University of Wurzburg, Wurzburg, Germany. MH 
      received honoraria from Celgene/BMS, Janssen, Kite/Gilead. The remaining authors 
      declare that the research was conducted in the absence of any commercial or 
      financial relationships that could be construed as a potential conflict of 
      interest.
EDAT- 2021/01/12 06:00
MHDA- 2021/07/08 06:00
PMCR- 2020/01/01
CRDT- 2021/01/11 05:37
PHST- 2020/10/22 00:00 [received]
PHST- 2020/11/24 00:00 [accepted]
PHST- 2021/01/11 05:37 [entrez]
PHST- 2021/01/12 06:00 [pubmed]
PHST- 2021/07/08 06:00 [medline]
PHST- 2020/01/01 00:00 [pmc-release]
AID - 10.3389/fimmu.2020.620312 [doi]
PST - epublish
SO  - Front Immunol. 2020 Dec 23;11:620312. doi: 10.3389/fimmu.2020.620312. eCollection 
      2020.